E-7386

Eisai's Phase Ib trial of E7386 in combination with lenvatinib demonstrated a 30% overall response rate in advanced endometrial cancer patients who progressed after platinum-based chemotherapy and immunotherapy.

Eisai will showcase long-term follow-up data from the Phase 3 LEAP-002 study evaluating lenvatinib plus pembrolizumab versus lenvatinib monotherapy in first-line unresectable hepatocellular carcinoma treatment.

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.